**Proteins** 

# **ARN5187**

Cat. No.: HY-103691 CAS No.: 1287451-26-6 Molecular Formula:  $C_{24}H_{32}FN_3O$ 

Molecular Weight: 397.53

Target: Autophagy; Apoptosis Pathway: Autophagy; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

**Product** Data Sheet

## **BIOLOGICAL ACTIVITY**

Description ARN5187 is a lysosomotropic REV-ERBβ ligand with a dual inhibitory activity toward REV-ERB-mediated transcriptional regulation and autophagy. ARN5187 shows lysosomotropic potency and cytotoxicity. ARN5187 induces apoptosis [1][2].

 $\mathsf{REV}\text{-}\mathsf{ERB}\beta^{[1]}$ IC<sub>50</sub> & Target

In Vitro ARN5187 (compound 1) (0-100  $\mu$ M; 48 h) shows cytotoxicity with EC<sub>50</sub> of 23.5  $\mu$ M in BT-474 cells and IC<sub>50</sub> of 30.14  $\mu$ M, >100  $\mu$ M for BT-474 and HMEC cells, respectively<sup>[1][2]</sup>.

ARN5187 (0-100 μM) activates the RevRE reporter in a concentration-dependent manner in HEK-293 cells<sup>[1]</sup>.

ARN5187 (25, 50  $\mu$ M) is a lysosomotropic-independent REV-ERB antagonistic activity<sup>[1]</sup>.

ARN5187 (50  $\mu$ M; 24 h) shows autophagy inhibition<sup>[1]</sup>.

ARN5187 (50  $\mu$ M; 2, 8, 24 h) effects autophagy formation and maturation<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity  $Assay^{[1]}$ 

Cell Line:	BT-474 cells
Concentration:	0-100 μΜ
Incubation Time:	48 h
Result:	Showed cytotoxicity with EC $_{50}$ of 23.5 $\mu\text{M}$ .
RT-PCR <sup>[1]</sup>	
Cell Line:	BT-474 cells
Concentration:	25, 50 μΜ
Incubation Time:	
Result:	Significantly enhanced the expression of BMAL1, PER1 and PEPCK in a dose-dependent manner.

Western Blot Analysis<sup>[1]</sup>

Cell Line:	BT-474 cells
Concentration:	50 μΜ
Incubation Time:	24 h
Result:	Significantly increased the expression of $\alpha$ -LC3-II, $\alpha$ -p62, $\alpha$ -Cleaved PARP.

## **REFERENCES**

[1]. De Mei C, et al. Dual inhibition of REV-ERB $\beta$  and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells. Oncogene. 2015 May 14;34(20):2597-608.

[2]. Torrente E, et al. Synthesis and in Vitro Anticancer Activity of the First Class of Dual Inhibitors of REV-ERB\$ and Autophagy. J Med Chem. 2015 Aug 13;58(15):5900-15.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA